Please ensure Javascript is enabled for purposes of website accessibility

2 Coronavirus Treatment Stocks to Buy Right Now

By George Budwell – Sep 9, 2020 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.

Companies attempting to develop effective coronavirus vaccines have taken center stage on Wall Street in 2020. Pfizer, Novavax, Vaxart, and others have all seen their share prices scream higher because of their COVID-19 programs.

The core reason is that the federal government's Operation Warp Speed has plowed approximately $11 billion into the development of vaccine candidates on accelerated timelines. The cold, hard truth, though, is that a vaccine alone will not be a panacea for this particular virus.

Up close image of the novel coronavirus.

Image Source: Getty Images.

The reason is that the vast majority of vaccines do not confer adequate levels of immunity in a number of patient populations, among them the elderly and the immunocompromised. That fact means that even if strong vaccines do hit the market, new, more effective coronavirus treatments -- especially for severely ill patients -- will still be required.

Eli Lilly (LLY 7.48%) and Kamada (KMDA 1.35%) are arguably two of the leading contenders in this under-appreciated area of the coronavirus investing landscape. Here's why. 

Eli Lilly: A potential blockbuster

Eli Lilly has been one of the best-performing big pharma stocks over the past few years thanks to its innovative approach toward business development. Briefly, it has expanded far beyond its core diabetes franchise to become a top player in the fields of oncology, neurology, and immunology. As a direct result, it has consistently posted top-notch earnings and revenue growth since the start of 2017.  

Now, the drugmaker is hoping to extend its winning streak by being among the first to develop a potent monoclonal antibody -- known as LY-CoV555 -- as a preventative COVID-19 treatment for elderly patients.  Eli Lilly partnered with AbCellera to develop the antibody, and last month, it launched a phase 3 trial to evaluate its ability to prevent SARS-CoV-2 infections in residents and staff at nursing homes. The initial results could be available for public consumption as soon as March, according to

Although Eli Lilly is facing considerable competition in this indication from the likes of AstraZeneca and Regeneron, Wall Street thinks the COVID-19 antibody market might be worth as much as $10 billion per year at its peak. Though the company surely won't have a monopoly in that lucrative market, there is a decent chance that LY-CoV555 could exceed $1 billion in annual sales in 2022. 

Kamada: A convalescent plasma therapy play

Kamada is a plasma-centered biopharmaceutical company with two FDA-approved products on the market: Glassia, a treatment for the inherited lung/liver disorder known as alpha-1 antitrypsin deficiency; and Kamrab, a preventative treatment for rabies.

Although neither of its commercial-stage products is a major cash cow, relatively speaking, Kamada has been posting respectable levels of revenue growth, positive free cash flow, and a steadily improving cash position over the past few quarters.

The biotech's main draw for investors, though, arguably isn't its current product line-up, but rather its experimental convalescent plasma therapy for COVID-19. On Aug. 23, President Trump announced that the FDA had issued an emergency use authorization for this intriguing treatment to be administered to hospitalized COVID-19 treatments.

Since then, the scientific community has raised concerns about the effectiveness of convalescent plasma therapy, given the lack of placebo-controlled clinical trials for them. But this skepticism probably won't dim the commercial potential for Kamada's therapy -- at least not in the short term.

The big picture is that this biotech has one of the most advanced plasma-based COVID-19 treatments in development, a fact which might translate into a healthy boost in its sales in the not-so-distant future.  

George Budwell owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$334.38 (7.48%) $23.28
Kamada Ltd. Stock Quote
Kamada Ltd.
$4.50 (1.35%) $0.06
Pfizer Inc. Stock Quote
Pfizer Inc.
$44.43 (0.77%) $0.34
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$705.42 (1.50%) $10.41
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$9,951.00 (-1.24%) $-125.00
Novavax, Inc. Stock Quote
Novavax, Inc.
$19.61 (-2.15%) $0.43
Vaxart, Inc. Stock Quote
Vaxart, Inc.
$2.33 (7.37%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.